Browsing Tag
PD-1/IL-2 Bispecific
1 post
Innovent begins IBI363 pivotal study in melanoma immunotherapy
Innovent Biologics, Inc. (HKEX: 01801), a global biopharmaceutical company specializing in innovative oncology therapies, has dosed the first…